Clinical treatment options for human cholangiocarcinoma (CC) are limited. c-MET, a high-affinity receptor for hepatocyte growth factor (HGF), is deregulated in many cancers. Its role in cholangiocarcinogenesis remains unclear. In current study, 23 corresponding tumor-and non-tumor tissues, taken from patients with intrahepatic (iCC) and perihilar cholangiocarcinoma (pCC), who underwent liver resection, were analyzed. The relationship of clinicopathological features and c-MET, as well as c-jun N-terminal kinase (JNK) was evaluated. The anti-tumor effects of Tivantinib, a small-molecule inhibitor with potent activity against the c-MET kinase, was investigated in three human CC cell lines, namely HUCC-T1, TFK-1, and EGI-1. In comparison with the results obtained in non-tumor tissue samples, c-MET was overexpressed in 91.3 % of tumor tissues (p < 0.01). The JNK expression was higher in tumor tissue compared with the corresponding non-tumor tissue sample in 17.4% patients (p < 0.01). The inhibition of aberrant c-MET expression in human CC cell lines was achieved by blocking the phosphorylation of c-MET with Tivantinib. Notable losses in cell viability and colony-forming capability were detected (p < 0.01). Synergistic activation of the JNK/ c-jun pathway was demonstrated after Tivantinib treatment. Knockdown of the JNK by siRNA or competitive binding of c-MET receptor by stimulation with HGF-antagonized anti-tumor effects of Tivantinib was observed. Our data suggest that inhibition of c-MET could be a possible alternative approach for the treatment of human CC, for which Tivantinib may an effective inhibitor. The synergistic activation of the JNK/c-jun pathway contributed to the elevated apoptosis in CC cells via treatment with Tivantinib.
Introduction
Untreated cholangiocarcinoma (CC) is one of most invasive malignancies with high mortality [1] [2] [3] [4] . Most patients are diagnosed at an advanced stage, for which radical surgical resection is not feasible. The combination of Gemcitabine and Cisplatin is the only first-line palliative treatment for those patients and has limited benefits [5] [6] [7] [8] .
The pro-tumorigenic function of c-MET, a high-affinity receptor of the hepatocyte growth factor (HGF), has a critical role in many solid tumors, including human CCs [9] [10] [11] [12] [13] [14] [15] [16] . c-MET activates multiple downstream signaling pathways such as the phosphtidyl inositol 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway, the mitogen activated protein kinase (MAPK) pathway, and the STAT pathway, and is also involved in cell proliferation, differentiation, survival, mortality, and movement 13, [17] [18] [19] . The aberrant expression of c-MET was recently considered as a potential target and biomarker in malignant tumors [20] [21] [22] . Although overexpression of c-MET has been described in patients with CC and in a mouse xenograft CC model, the precise function of c-MET signaling in cholangiocarcinogenesis still remains unclear 15, 16, 23, 24 . The aim of this study was to explore the expression of c-MET in corresponding non-tumor and tumor tissues from CC patients, and its relationship with numerous clinicopathological factors. Tivantinib, a smallmolecule kinase inhibitor with potent activity against c-MET, was investigated as an alternative therapeutic approach for CC in vitro.
Methods

Human tissue and immunofluorescence histochemistry
Twenty-three corresponding tumor-and non-tumor tissues were collected from patients with intrahepatic (iCC) and perihilar CC (pCC), who underwent liver resection. Clinicopathological characteristics of the patients are shown in Table 1 . Tissue slides (7 μm) were soaked in 100 μL of goat serum blocking solution for 1 h after being washed twice with Tris-buffered saline with Tween20 (TBST) buffer for 5 min each. The slides were incubated overnight at 4°C with the primary antibody at a concentration of 1 µg/mL. Cytokeratin 19 (CK19), which is normally expressed in the lining of the gastroenteropancreatic and hepatobiliary tracts, was applied in immunofluorescence histochemistry to distinguish the biliary duct system from other liver cells 25, 26 . After three washes in phosphate-buffered saline (PBS), the tissue sections were incubated with 100 μL of secondary antibody in a dark, humid chamber at room temperature for 1 h. Finally, 100 μL of 4′,6-diamidino-2-phenylindole (DAPI) solution (Sigma-Aldrich, Munich, Germany) was introduced into each tissue area for 10 min before being counterstained with Mayer's hematoxylin for 10 s, dehydrated in ethanol, and mounted. Immunohistochemistry was examined using a Zeiss Axiovert 40 CFl microscope. This study was carried out with the patients' informed consent and approval from the local ethics committee. The approval number is 159/2002 and followed the guidelines stated in the Declaration of Helsinki.
Cell lines culture and reagents
HUCC-T1, TFK-1, and EGI-1 (Riken BRC Cell Bank (Tsukuba, Ibaraki, Japan), German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany)) were used for in vitro experiments. All cell lines were cultivated in RPMI-1640 medium supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin in 5 % CO 2 at 37°C. Tivantinib (ARQ197, Selleck Chemicals, USA), Apitolisib (GDC-0980, RG7422, Selleck Chemicals, USA), and Refametinib (RDEA119, Bay 86-9766, Selleck Chemicals, USA) were dissolved in 100% dimethyl sulfoxideand stored at −20°C. Recombinant human HGF was purchased from Sigma-Aldrich, Munich, Germany.
Cell viability assay
Cells were seeded onto 96-well plates at various cell densities to avoid overgrowth (8 × 10 3 /well) and were treated with increasing concentrations of Tivantinib or a combination of Apitolisib and Refametinib. To investigate the effect of Tivantinib or the combined treatments on cell viability at different concentrations, the cells were kept in culture for 1, 2, 3, and 6 days. At the time points 1, 2, and 3 days, 20 μL of MTT (3-(4,5-dimethylthiazol-2-yl)- Briefly, the PrestoBlue solution (22 µL) was added into each well after 2 h of incubation for the 6-day treatment condition, plates were then placed back into the incubator for a further 2 h of incubation, after which absorbance was measured at 570 nm for excitation and 600 nm for emission.
Colony-formation assay
Cells were trypsinized and plated in 6-well plates containing 200 cells per well. After overnight attachment, the cells were exposed to treatment conditions for 48 h. The media was replaced with fresh media and then the plates were maintained at 37°C. Fourteen days later, the cells were fixed and stained using crystal violet (20% ethanol and 0.5% crystal violet in water). The number of colonies, defined as > 50 cells/colony, were counted. Triplicate wells were set up for each condition under investigation.
Flow cytometry
Cells (1 × 10 5 to 2 × 10 5 ) were seeded in six-well plates and treated after being left to incubate overnight. Fluorescence-activated cell sorting (FACS; CellQuest analysis program, BD Biosciences, Heidelberg, Germany) was performed to detect the sub-G1 cell fraction. This was done to determine apoptosis and the respective phases of the cell cycle after propidium iodide (PI) staining as previously described 27 . In addition, apoptosis was assessed morphologically using Hoechst 33342 staining and fluorescence microscopy.
Immunofluorescence cytochemistry
Cells seeded on cover slides were fixed with ice-cold methanol. After blocking, the cells were incubated at 37°C for 45 min with the primary antibody. An antibody diluent with background reducing components from Dako (Glostrup, Denmark) was used to dilute the primary antibodies and as a negative control. After five washes in PBS, the cells were incubated with the fluorochrome-conjugated secondary antibody at 37°C for 45 min before being washed again with PBS. Nuclear staining was achieved with DAPI (Sigma-Aldrich, Munich, Germany). Finally, cover slides were mounted in a fluorescence mounting medium obtained from Dako.
siRNA transfection
For c-jun N-terminal protein kinase (JNK) and c-jun knockdown in human CC cell lines, the following predesigned and pre-validated small interfering RNAs (siR-NAs) were purchased from Cell Signaling Technology: SignalSilence ® SAPK/JNK siRNA II (catalog number 6233) and SignalSilence ® c-jun siRNA II (catalog number 6204). HuCC-T1 and EGI-1 cell lines were transfected with siRNA using Lipofectamine® 2000 Transfection Reagent (Thermo Scientific, Rockford, IL, USA) as per the supplier's protocol. Transfection efficiency was evaluated after 24, 48, and 72 h using western blotting. The apoptotic effect of Tivantinib on human CC lines after siRNA transfection was detected using MTT assay and FACS.
Western blotting
Cells were lysed using RIPA buffer (Sigma-Aldrich, Munich, Germany) for 10 min on ice, followed by centrifugation at 16,110 × g for 15 min at 4°C. The supernatant was collected and the protein concentration was determined using a BCA™ Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). Whole cell extracts (20 μg) were heated with LDS sample buffer (Invitrogen, Carlsbad, CA, USA) at 70°C for 10 min, separated using SDSpolyacrylamide gel electrophoresisin 4-12 % Bis-Tris gel (Invitrogen, Carlsbad, CA, USA), and transferred to the nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). After blocking for 1 h, the membrane was incubated overnight with primary antibodies at 4°C. Subsequently, the membrane was probed using horseradish peroxidaseconjugated secondary antibody for 1 h at room temperature. The bands were visualized using a West PICO chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA) and photographed using an image acquisition system (Vilber, Eberhardzell, Germany).
Antibodies
The following antibodies were used: Actin, p-Met, c-MET, BCL-XL, FADD, p-Bad, bim, cleaved caspase-8, cleaved caspase-3, Phospho-p44/42 MAPK (Erk1/2), p44/ 42 MAPK (Erk1/2), p-c-jun, p-AKT, AKT, p-Raf, c-Raf Phospho-MEK1/2, MEK1/2 (Cell Signaling, Frankfurt, Germany); caspase-8, JNK1, and p-JNK (Santa Cruz, Heidelberg, Germany); CK19, c-jun, and p-c-jun (Abcam, Cambridge, UK); c-MET neutralizing antibody (Sigma-Aldrich, Munich, Germany); and the secondary antibodies for goat anti-rabbit and goat anti-mouse (LI-COR Biosciences GmbH, Bad Homburg, Germany).
Statistical analysis
The IC 50 , t-test, and one-way analysis of variance were calculated using IBM SPSS Statistics 24.0. The figures were plotted using GraphPad Prism 6.0. The values obtained are the mean (± SEM) of three replicates. Statistical difference was considered significant when p ≤ 0.05.
Results
c-MET is aberrantly expressed in tumor tissue when compared with the corresponding non-tumor tissue
To validate the activation of c-MET signaling in CC carcinogenesis, the activation of c-MET expression was measured in 23 corresponding tumor-and non-tumor tissue samples taken from patients with iCC and pCC. Expression of c-MET in both the tumor-and the corresponding non-tumor tissues is presented in Fig. 1a . In comparison with non-tumor tissues, c-MET was overexpressed in 91.3% of tumor tissue samples (21/23, p < 0.01). In each TNM stage or tumor histological grade, there were more patients who had a greater expression of c-MET in the tumor tissue than in the non-tumor tissue ( Fig. 1b, c) .
Notable losses in cell viability and colony-forming capability were caused by Tivantinib in human CC cell lines
Tivantinib treatment was shown to cause a dosedependent loss in cell viability with IC 50 values in HuCC-T1(127.8 nM), TFK-1(200.2 nM), and EGI-1 (151.5 nM) ( Fig. 2b) . This matched the various naive levels of c-MET expression in these cell lines, which had been obtained using western blotting ( Fig. 2a ). The cell lines expressing high c-MET showed more sensitivity to the c-MET inhibitor Tivantinib. Likewise, colonyforming assays further confirmed a reduction in the number and size of colonies in the cells treated with Tivantinib ( Fig. 2c ). 
Tivantinib application inhibited CC growth by inducting apoptosis independent of c-MET downstream pathways
To evaluate the mechanism by which Tivantinib causes loss of viability in human CC cell lines, cell apoptosis DAPI staining, several parameters were investigated, including sub-G1 cell fraction detection during FACS analysis after PI staining, the presence of apoptotic proteins via western blotting experiments, and immunofluorescence cytochemistry. This was based on recent evidence in which apoptosis was shown to be strongly induced in the presence of Tivantinib [27] [28] [29] . Induction of apoptosis was observable at Tivantinib concentrations of 500 and 5000 nM. In addition, cells showed apoptotic features, such as DNA fragments, after 72 h of incubation during DAPI staining (Fig. 3a) . FACS indicated an increase in sub-G1 events in both a time-and dosedependent manner after Tivantinib application (Fig. 3b ). Cleaved caspase-3, cleaved caspase-8, and FADD were highly expressed, whereas BCL-xl, p-Met, and c-MET were downregulated (Fig. 3c ). Upregulation of activated caspase-3 cleavage and caspase-8 was confirmed using immunofluorescence cytochemistry (Fig. 3d , Supplementary Figures 1A-B) .
To further investigate the pro-apoptotic mechanism of Tivantinib, two main downstream c-MET pathways were analyzed: the Pi3k/Akt/mTOR and Ras/Raf/MEK/ERK pathways. Using western blotting analysis, high expression of key proteins from both pathways were detected after the addition of Tivantinib ( Supplementary Fig. 2A-B) . Similarly, immunoblotting results were also observable in the pancreatic cancer cell line Capan-1 and the hepatocellular carcinoma cell line Huh7 in the presence of Tivantinib (Supplementary Figure 2C) . Downregulation of the Pi3k/Akt/mTOR pathway by the Pi3k inhibitor Apitolisib or the Ras/Raf/MEK/ERK pathway by the MEK inhibitor Refametinib did not enhance the anti-tumor effect Tivantinib had on the viability of CC cells. This implied that the pro-apoptotic activity of Tivantinib was independent and unaffected by any blockage of c-MET downstream pathways. The JNK/c-jun pathway is known to have a key role in the apoptosis process in many treated tumors [30] [31] [32] [33] . As shown by the increasing expression of phosphorylated and total JNK and its downstream proteins such as p-c jun, Bim, and p-Bad in western blotting analysis exposed at 24, 48, and 72 h after the addition of Tivantinib, activation of the JNK/c-jun pathway contributed to the synergistic induction of apoptosis by Tivantinib in CC cells (Fig. 4a, b ). In short time expose, Tivantinib had weak effect on the induction of the p-JNK expression but caused high JNK and p-c-jun expression ( Fig. 4c ). Moreover, in immunofluorescence cytochemistry analysis, the localization of upregulated c-jun at phosphorylated and total level, and in correspondence with the JNK/p-JNK was demonstrated ( Fig. 4d , Supplementary  Figures 3A-B) .
To further assess the role of the JNK/c-jun pathway in underlying apoptosis processes, siRNA transfection targeting JNK and c-jun was conducted. As shown in Fig. 5a , b, silencing JNK by simultaneous co-transfection of specific siRNA sequences in HuCC-T1 and EGI-1 cells led to a decrease in Tivantinib-induced apoptosis over the course of 24 h. Competitive binding of the c-MET receptor via stimulation with HGF promoted CC cell growth by increased expression of the c-MET pathway. Simultaneously, the anti-tumor effects of Tivantinib antagonized due to decreased expression of the JNK pathway (Fig. 5c ). However, no significant decrease in sub-G1 events during the knockdown of c-jun was observed ( Fig. 5d, e ). Next, c-MET neutralizing antibody was introduced to validate the role of JNK/c-jun pathway in current study (Fig. 5f ). Similar to Tivantinib, blocking the c-MET receptor at 24, 48, and 72 h caused upregulated expression of Cleaved caspase-3 and FADD, and activation of JNK/c-jun pathway.
Low expression of JNK1 in tumor tissue in CC patients
High expression of JNK1 was detected in tumor tissue samples compared to corresponding non-tumor tissue in 17.4% of patients (4/23, p < 0.01) ( Table 2 ). However, JNK1 was overexpressed in non-tumor tissues of most patients (16/23 patients). No difference was detected between the non-and tumor tissues in three patients (Fig. 6a ). There was no difference in the expression of JNK1 in each TNM stage subgroup or between the various tumor histological grade subgroups ( Fig. 6b and Table 2 , p > 0.05).
Discussion
c-MET overexpression is well reported in multiple carcinomas 10, 34, 35 . In the present study, c-MET overexpression was found in CC tumor tissues compared with non-tumor tissues. It is hypothesized that c-MET might be a promising therapeutic target in CC treatment.
A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being investigated in phase I, II, and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity of these agents, along with an acceptable toxicity profile [20] [21] [22] . In the present study, Tivantinib, a non-selective Met inhibitor that stabilizes its non-phosphorylated inactive conformation, was used to inhibit the c-MET expression in vitro 36, 37 . However, there are conflicting clinical trial results. In some cases, Tivantinib failed two phase III studies involving secondline treatment of Met-high, advanced, hepatocellular carcinoma (METIV-HCC/JET-HCC), despite its success during phase II studies. The reasons for this might be multifactorial and discussion centers around trial design, inadequacies in the selection of patients according to tumor c-MET status, unclear definition for primary c-MET expression as biomarker for treatment, the inevitable upregulation of c-MET, which had been exposed during first-line treatments such as Sorafenib, and differences in implementation of Tivantinib during studies 22, [38] [39] [40] [41] [42] . A recent systematic review and metaanalysis on the efficacy and safety of Tivantinib for the treatment of solid tumors concluded that Tivantinib prolonged the progression-free survival, but not the overall survival in patients 43 . This was similar to the results of a phase III study involving epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer 44 . So far, there is limited information about Met The study demonstrated that targeting c-MET using Tivantinib led to a dose-and time-dependent decrease in the growth, viability, and colony formation in human CC cell lines. Compared with TFK-1, a cell line with low baseline levels of c-MET expression, HuCC-T1 and EGI-1, both of which had relatively high baseline levels of c-MET expression, were found to be more sensitive to Tivantinib. This indicated that Tivantinib inhibited the activation of c-MET signaling and is also involved in the progression of CC, as it effectively inhibits both the full and the phosphorylated form of c-MET. Further, based on recent evidence on its apoptosis-inducing ability, Tivantinib was shown to cause cleavage of Procaspase-3 and -8 followed by the FADD. Cleavage of Caspase-8 was a hallmark of extrinsic apoptotic pathway activation, whereas cleavage of Caspase-3 represented the intrinsic apoptosis involved 45 .
c-MET engagement participates in multiple transduction pathways 13, [17] [18] [19] . Different downstream targets of the c-MET signaling pathway were analyzed to investigate Tivantinib's pro-apoptotic mechanisms. This is in contrast to previous studies with c-MET inhibitors [46] [47] [48] in which high expression of p-AKT, AKT, p-raf, c-raf, p-ERK, and ERK after 24 h of exposure to Tivantinib was observed and confirmed in CC cell lines, the pancreatic cancer cell line Capan-1, and the hepatocellular carcinoma cell line Huh7. However, in previous studies with c-MET inhibitors, combination with the Pi3k inhibitor Apitolisib or the MEK inhibitor Refametinib did not affect the anti-tumor efficacy of Tivantinib. This indicated that activation of c-MET downstream pathways, the Pi3k/Akt/mTOR pathway, and the MAPK/ERK pathway seemed to have a marginal role in triggering apoptosis. As both the intrinsic and extrinsic apoptotic pathways were activated in CC cells during Tivantinib treatment, cell apoptosis related to pathways were assessed. Data indicated that Tivantinib activated the JNK/c-jun pathway and induced CC cells apoptosis. The data on JNK was also confirmed by blocking c-MET receptor with neutralizing antibody. Apoptosis was reduced via a decrease in JNK through siRNA transfection or competitive binding of the c-MET receptor by HGF, but not via the silencing of c-jun. The JNK/c-jun pathway could be activated using multiple factors and c-jun activation could be independent or dependent on this pathway 49, 50 . Present results indicated that the JNK/c-jun pathway might be involved in the synergistic apoptotic effect exhibited by Tivantinib; among others, it was JNK, rather than its downstream protein c-jun, which had a role in Tivantinib-induced apoptosis. Tivantinib might antagonize the effect of c-MET downmediated expression of JNK to proceed the apoptotic pathway, the effect of c-jun might not be key role during this process. This was in agreement with previous studies in which c-jun was not essential for apoptosis 51, 52 .
In contrast, the JNK is a subfamily of the MAPK superfamily, which specifically phosphorylates the transcription factor c-Jun on its N-terminal transactivation domain at two serine residues Ser63 and Ser73 53 . JNK is a key regulator in many cellular events. Apoptosis mediated by the JNK/c-jun pathway was influenced by the cell type, the duration of stimulation, or its upstream and downstream signal pathways. The JNK/c-jun pathway could activate or inhibit apoptosis 50, 54 . The present study confirmed that when exposed to Tivantinib, activated JNK was responsible for caspase-3 activation, followed by the downstream proteins p-c jun, bim, and p-Bad.
In previous clinical trials, high c-MET expression was described as an incidental biomarker of tumor sensitivity to the anti-tumor activity of Tivantinib 38, 41 . Here, it was demonstrated that Tivantinib also activated JNK and its pathway. JNK, in addition to MET overexpression, could be a potential predictor of Tivantinib efficacy in CC. Therefore, the expression of JNK1 in non-tumor and the corresponding tumor region from patients with CC was detected. There is evidence that JNKs, especially JNK1, had a critical role in death receptor-initiated extrinsic and mitochondrial intrinsic apoptotic pathways [30] [31] [32] [33] [55] [56] [57] . Based on this, it could be hypothesized that CC arising from epithelial origin may already lose the ability to quickly renew epithelial through JNK-mediated cell-programmed death due to tumorous immortality and heterogenesis. In this study, JNK1 was overexpressed in non-tumor tissues compared with the corresponding tumor tissues. There was no difference in the expression of JNK regarding each TNM stage and tumor histological grade. This illustrated that JNK, similar to c-MET, may participate in each developmental stage of cholangiocarcinogenesis and could be a possible alternative predictor for Tivantinib treatment. However, to prove this hypothesis, additional research is needed to define the optimal selection strategy for patients based on the JNK status combined with/without c-MET expression for Tivantinib treatment in CC. Moreover, In summary, inhibition of c-MET could be a possible alternative approach for the treatment of human CC, for which Tivantinib may an effective inhibitor. The synergistic activation of the JNK/c-jun pathway contributed to elevated apoptosis in CC cells through the treatment with Tivantinib. The data presented indicate great therapeutic potential for CC treatment with c-MET inhibition.
